Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 19/20 | 0.58 |
| ▸ | AR | P10275 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595579 | 1.00 | PGR (0.58) | PGRARCYP2C19CYP2D6CYP2C9 | |
| SCHEMBL4896141 | 0.91 | PGR (0.61) | PGRARCYP2C19CYP2D6CYP2C9 | |
| SCHEMBL4594877 | 0.91 | PGR (0.61) | PGRARCYP2C19CYP2D6CYP2C9 | |
| SCHEMBL4904645 | 0.91 | PGR (0.61) | PGRARCYP2C19CYP2D6CYP2C9 | |
| SCHEMBL4594557 | 0.88 | PGR (0.62) | PGRARCYP2C19CYP2D6CYP2C9 | |
| SCHEMBL4595648 | 0.88 | PGR (0.62) | PGRARCYP2C19CYP2D6CYP2C9 | |
| SCHEMBL4906635 | 0.86 | PGR (0.78) | PGRARCYP2C19CYP2D6CYP2C9 | |
| SCHEMBL4904515 | 0.86 | PGR (0.78) | PGRARCYP2C19CYP2D6CYP2C9 | |
| SCHEMBL4901392 | 0.85 | AR (0.71) | PGRAR | |
| SCHEMBL4907347 | 0.85 | AR (0.71) | PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194536-A1 | Cyanoarylamines | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | claimed |
| EP-1871379-A2 | CYANOARYLAMINES | Smithkline Beecham Corporation (US) | 2008-01-02 | — | — | EP | claimed |
| WO-2006113552-A2 | CYANOARYLAMINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | claimed |
| US-20080194536-A1 | Cyanoarylamines | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080194536-A1 | Cyanoarylamines | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080194536-A1 | Cyanoarylamines | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194536-A1 | Cyanoarylamines | EDNRA, CYP19A1, HSD17B11 | PGR 64/4885AR 84/4885CYP2C19 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.